Maury Raycroft
Stock Analyst at Jefferies
(0.56)
# 3,945
Out of 4,884 analysts
47
Total ratings
21.62%
Success rate
-17.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $3.66 | -4.37% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $7.71 | +587.42% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $2.78 | +187.77% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.53 | +469.37% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $2.87 | +143.90% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.44 | +316.67% | 1 | Nov 18, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $5.70 | +233.33% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $3.11 | +382.32% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $18.85 | +106.90% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $0.70 | +763.06% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.67 | +1,277.25% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $7.13 | +2,634.92% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $8.94 | +23.04% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $24.00 | -75.00% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $16.79 | +346.69% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $331.91 | -30.10% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.82 | +128.22% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $10.00 | +170.00% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $2.23 | +124.22% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $13.79 | +248.08% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $5.81 | +519.62% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $5.03 | +1,987.48% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $52.17 | +229.69% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.58 | +1,721.71% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $4.58 | +4,921.83% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $10.74 | +291.06% | 3 | Nov 1, 2017 |
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $3.66
Upside: -4.37%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $7.71
Upside: +587.42%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.78
Upside: +187.77%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.53
Upside: +469.37%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.87
Upside: +143.90%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.44
Upside: +316.67%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $5.70
Upside: +233.33%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $3.11
Upside: +382.32%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $18.85
Upside: +106.90%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.70
Upside: +763.06%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.67
Upside: +1,277.25%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $7.13
Upside: +2,634.92%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $8.94
Upside: +23.04%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $24.00
Upside: -75.00%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $16.79
Upside: +346.69%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $331.91
Upside: -30.10%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $4.82
Upside: +128.22%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $10.00
Upside: +170.00%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $2.23
Upside: +124.22%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $13.79
Upside: +248.08%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $5.81
Upside: +519.62%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $5.03
Upside: +1,987.48%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $52.17
Upside: +229.69%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.58
Upside: +1,721.71%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $4.58
Upside: +4,921.83%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $10.74
Upside: +291.06%